The Role of HTA for Biosimilars Mestre-Ferrandiz 2014

4,303 views

Published on

At the 34th Spanish Health Economics Association annual meeting, Jorge Mestre-Ferrandiz reviewed the results of the discussions of an expert panel about the role of HTA for biosimilars. Representatives from the three UK HTA agencies, the MHRA, and academia discussed which HTA methods are most appropriate for biosimilars in specific situations.

0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
4,303
On SlideShare
0
From Embeds
0
Number of Embeds
2,668
Actions
Shares
0
Downloads
0
Comments
0
Likes
2
Embeds 0
No embeds

No notes for slide

The Role of HTA for Biosimilars Mestre-Ferrandiz 2014

  1. 1. Jorge Mestre-Ferrandiz AES 34th Annual Meeting Pamplona • 27–30 May 2014 What Is the Role of HTA for Biosimilars?
  2. 2. What is the role of HTA for biosimilars? 30/05/2014 2 Agenda • Some definitions • Introduction & context • HTA for biosimilars – UK experience • Key results • Conclusions
  3. 3. What is the role of HTA for biosimilars? 30/05/2014 3 Definitions • Biological medicines: Biotherapeutic medicines are medicines whose active ingredients are or are derived from proteins (such as growth hormone, insulin, antibodies) and other substances produced by living organisms (such as cells, viruses and bacteria). They are larger and more complex than chemically-synthesised medicines and their characteristics and properties are typically dependent on the manufacturing process itself. Biotherapeutic medicines can also be referred to as biologics, biological medicines and biopharmaceuticals (IFPMA, 2012) • Biosimilar: A biosimilar medicine is a biological medicine that is developed to be similar to an existing biological medicine (the 'reference medicine'). Biosimilars are not the same as generics, which have simpler chemical structures and are considered to be identical to their reference medicines (EMA, 2012)
  4. 4. What is the role of HTA for biosimilars? 30/05/2014 4 Now and the future… • Over the past 10 years there has been a rapid worldwide increase in the number of biological medicines that have received regulatory approval • A number of important, top-selling biological medicines have lost, or will be losing patent protection over the next five years – especially tumour necrosis factor (TNF) inhibitors (anti-TNFs) for rheumatoid arthritis (RA), MAbs for oncology and insulins for diabetes • These categories include drugs such as Herceptin, Enbrel, Humalog, MabThera, Remicade and Aranesp (IMS, 2011) significantly increasing the potential biosimilars market • By 2016, approximately $US64 billion worth of biological therapies globally will be going off patent and be open to biosimilar competition (Dranitsaris et al., 2011)
  5. 5. What is the role of HTA for biosimilars? 30/05/2014 5 Objectives • 2013 position papers by the Association of the British Pharmaceutical Industry • Seven recommendations covering areas where it believes action is needed by regulators, HTA agencies, NHS commissioners and NHS healthcare professionals who prescribe or dispense originator biologics and biosimilar medicines. • In particular, Recommendation 5 states that 'Biosimilar medicines should be subject to health technology assessment (HTA) processes in the UK': – 'Biosimilar products should be subject to health technology assessment in order that they can be assessed for clinical and cost effectiveness using the appropriate evidence base. It should be stated clearly in the main section of resultant HTA guidance that is issued that the medicine appraised is a biosimilar. – 'Biosimilar products should be recorded on UK PharmaScan by companies as soon as they enter Phase III clinical trials or within three years of their expected launch date so they can be reported upon by the NHS horizon scanning agencies for HTA topic selection purposes. – 'The Scottish Medicines Consortium (SMC) and All Wales Medicine Strategy Group (AWMSG) (where appropriate) should routinely appraise biosimilar medicines and the NICE topic selection process should be used to identify those biosimilars which should be subject to NICE appraisal' ABPI position paper available at: http://www.abpi.org.uk/our-work/library/industry/Pages/biosimilars-position-paper.aspx
  6. 6. What is the role of HTA for biosimilars? 30/05/2014 6 Objectives • Amgen provided the Office of Health Economics (OHE) an unrestricted research grant to explore the appropriateness of Recommendation 5, in a way that meets regulatory and safety requirements (as stated in Recommendations 1- 4 – next slide) whilst enabling an appropriate assessment of value to be made
  7. 7. What is the role of HTA for biosimilars? 30/05/2014 7 ABPI Recommendations • Recommendation 1: All biologic/biosimilar prescriptions should be written by brand name and not by International Nonproprietary Name (INN) • Recommendation 2: Automatic substitution is not appropriate for biological medicines including biosimilars. A biological medicine including a biosimilar, must only be substituted under the direct supervision and with the consent of the treating physician • Recommendation 3: Patients should be kept fully informed about their medication and should be consulted if any changes to their treatment are made • Recommendation 4: The summary of medicinal product characteristics (SmPC) for a biosimilar medicine should clearly indicate the source of information contained within it, such as relevant data from its clinical development programme and clinical data derived from the originator or reference biological medicine
  8. 8. What is the role of HTA for biosimilars? 30/05/2014 8 EMA Regulatory Process • An extensive comparability exercise is required in order to demonstrate that the applicant biosimilar medicine and reference product have similar profiles in quality, safety and efficacy • Different amounts of pre-clinical and clinical data are required on a case-by-case basis to ascertain the safety and efficacy of biosimilars • Assessments of the substitution and interchangeability of the biosimilars with the originator product are not part of the scientific evaluation leading to the granting of a MA (EMA, 2012) – Member State competency
  9. 9. What is the role of HTA for biosimilars? 30/05/2014 9 As of December 2013, the EMA has authorised 18 biosimilars to be marketed under different brand names in four specific therapy areas
  10. 10. What is the role of HTA for biosimilars? 30/05/2014 10 Definitions • EPOs: erythropoietins. Hormone produced by the kidney to regulate red blood cell production. Used for treatment of anaemia associated with chronic kidney disease, cancer and reduction of transfusion requirements in adult patients receiving chemotherapy • G-CSFs: granulocyte-colony-stimulating-factor. Filgrastims. Used to reduce the risk of infection in patients with some tumours, who are receiving strong chemotherapy that may cause severe neutropenia with fever • Growth hormones: somatropin. Used for children and adults
  11. 11. What is the role of HTA for biosimilars? 30/05/2014 11 Methodology 1. Literature review 2. Roundtable prepared, run and chaired by OHE (25 Feb 2013) • with key stakeholders (regulators, UK HTA bodies and academics) • to discuss the appropriate use of HTA for biosimilars in the UK
  12. 12. What is the role of HTA for biosimilars? 30/05/2014 12 HTA experience in the UK • The Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG) have similar current positions on biosimilars: • Biosimilars should undergo a full submission (rather than the limited/abbreviated one) • The AWMSG states that cost-minimisation analyses (CMA) are appropriate for biosimilars only when: • The reference product has been recommended by NICE or AWMSG for the intended indication; or • When the reference product is already in widespread use for the indication (evidence of this would be required). • When the reference product has not been recommended by NICE/AWMSG for the intended indication, or if the reference product is not in widespread use, a cost-utility analysis is required, comparing the biosimilar against some other relevant comparator, using clinical data relating to the reference product, if necessary
  13. 13. What is the role of HTA for biosimilars? 30/05/2014 13 HTA experience in the UK • The SMC position, however, does not refer explicitly to the appropriate type of economic analysis under the situation when the reference product has not been accepted by the SMC – contrary to the AWMSG position • NICE does not have a position statement on biosimilars. To date NICE has appraised biosimilars in one technology appraisal (for growth hormones), but these were not treated differently than the other products included • Draft for consultation – watch this space!
  14. 14. What is the role of HTA for biosimilars? 30/05/2014 14 HTA experience in the UK • The AWMSG has reviewed five biosimilar filgrastims – all of them, except one, have been recommended, under a full submission, using CMA or budget impact analysis. • There is no appraisal for the reference product for these biosimilars • The AMWSG earlier decisions on the EPOs, including for the reference product Eprex, have been superseded by NICE's guidance. The decisions are mixed in terms of accepting and rejecting the biosimilars and the reference product • The SMC has reviewed to date eight biosimilars, seven of them after full submissions and all with CMA. • The four filgastrims were compared against their reference product but we did not identify an SMC decision for this reference product • All four were recommended
  15. 15. What is the role of HTA for biosimilars? 30/05/2014 16 Conclusions • In terms of HTA, the majority view wanted flexibility in the choice of processes and methods to consider whether or not to assess biosimilars from a health economics perspective • Selection process needs to be transparent and based on clear, consistent criteria • Any recommendations resulting from HTAs should be cognisant of regulatory and safety recommendations from EMA and MHRA (such as prescribing by brand name and no automatic substitution) • An HTA assessment should focus on value, either through a cost-minimisation analysis or a cost-utility analysis
  16. 16. What is the role of HTA for biosimilars? 30/05/2014 17 Available to download at www.ohe.org
  17. 17. What is the role of HTA for biosimilars? 30/05/2014 18 To enquire about additional information and analyses, please contact Dr. Jorge Mestre- Ferrandiz at jmestre-ferrandiz@ohe.org. To keep up with the latest news and research, subscribe to our blog, OHE News and follow us on Twitter @OHENews, LinkedIn and SlideShare. The Office of Health Economics is a research and consulting organisation that has been providing specialised research, analysis and expertise on a range of health care and life sciences issues and topics for over 50 years. OHE's publications may be downloaded free of charge for registered users of its website. Office of Health Economics Southside, 7th Floor 105 Victoria Street London SW1E 6QT United Kingdom +44 20 7747 8850 www.ohe.org Contacts

×